Gujarat: PM Modi reviews vaccine development at Zydus Cadila facility

AHMEDABAD: Prime Minister Narendra Modi on Saturday began his three-city visit to review coronavirus vaccine development work by going to pharma major Zydus Cadila’s manufacturing facility near Ahmedabad. Wearing a PPE kit, Modi reviewed the vaccine development process at the Zydus Cadila research centre in Changodar industrial area, over 20 km from Ahmedabad.

After his arrival at Ahmedabad airport from Delhi shortly after 9 am, Modi flew to the Zydus Cadila plant and held discussions with the promoters and executives of the company, an official said.

Modi spent over an hour at the plant, before leaving for the airport, from where will fly to Hyderabad.

Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials from August.

In Hyderabad, Modi is scheduled to visit vaccine maker Bharat Biotech’s facility.

After landing at Hakimpet Air Force station, Modi will reach Bharat Biotech’s facility at Genome Valley at 1.30 pm. The facility is around 50 km from Hyderabad.

Bharat Biotech’s Covaxin is undergoing phase-3 trials.

After his hour-long visit to the facility, the PM will proceed to Pune, where he will visit the Serum Institute of India (SII), which has partnered with global pharma giant AstraZeneca and the Oxford University for the vaccine.

The prime minister will reach Serum Institute campus around 4.30 pm, an official said.

Modi’s hour-long visit to SII is aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanism, he said.

The PM will fly back to Delhi in the evening, the official said.

  • Related Posts

    Unapproved drops for dry eyes pose risks: Govt

    NEW DELHI: Flagging that certain yet-to-be-approved dry eye relief drops are being sold in the market, the central drugs regulator has asked states to cancel any permissions granted for these…

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    The global conversation around obesity and type 2 diabetes management has shifted dramatically in recent years, largely due to the rise of GLP-1 receptor compounds. Among them, semaglutide has emerged…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Unapproved drops for dry eyes pose risks: Govt

    Unapproved drops for dry eyes pose risks: Govt

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Inaugural Conference of ‘Critical Nephrology Society of India’ (CNSI) puts Best Foot Forward

    Govt highlights multi-layer framework to curb misleading advertisements

    Govt highlights multi-layer framework to curb misleading advertisements

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Major breakhthrough: Sonbhadra cops nab codeine syrup racket handler in Bengal

    Study finds rising resistance to a last-resort antibiotic in Africa

    Study finds rising resistance to a last-resort antibiotic in Africa